RECRUITING

GEMINI-NSCLC: NSCLC Biomarker Study

Talk to us

Conditions

Non-Small Cell Lung CancerCancerOncologyObservationalGenomic ProfilingPrecision medicineNSCLCNGSBiomarkers

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Official Title

TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)

Quick Facts

Study Start:2022-06-22
Study Completion:2029-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05236114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

GEMINI NSCLC
CONTACT
(833) 514-4187
gemini-nsclc@tempus.com

Principal Investigator

Virginia Rhodes, MD
PRINCIPAL_INVESTIGATOR
Tempus AI, Inc.

Study Locations (Sites)

Alabama Oncology
Birmingham, Alabama, 35223
United States
Mercy Clinic Oncology - Fort Smith
Fort Smith, Arkansas, 72903
United States
MemorialCare
Fountain Valley, California, 92708
United States
Cancer and Blood Specialty Clinic
Los Alamitos, California, 90720
United States
Eastern CT and Hematology and Oncology Associates
Norwich, Connecticut, 06360
United States
Woodlands Medical Specialists
Pensacola, Florida, 32503
United States
Morehouse School of Medicine (MSM)
Atlanta, Georgia, 30310
United States
Hawaii Cancer Care
Honolulu, Hawaii, 96813
United States
Southern Illinois Hospital Services
Carterville, Illinois, 62918
United States
Cancer Care Specialists of Illinois
Decatur, Illinois, 62526
United States
Northwestern University
Evanston, Illinois, 60208
United States
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521
United States
Community Health Network
Indianapolis, Indiana, 46250
United States
University of Iowa
Iowa City, Iowa, 52242
United States
Johns Hopkins University
Baltimore, Maryland, 21287
United States
The Center for Cancer and Blood Disorder
Bethesda, Maryland, 20817
United States
Mercy Clinic Oncology and Hematology - Joplin
Joplin, Missouri, 64804
United States
Lake Regional Health System
Osage Beach, Missouri, 65065
United States
Mercy Clinic Oncology and Hematology - Sindelar Cancer Center
Saint Louis, Missouri, 63128
United States
Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center
Saint Louis, Missouri, 63141
United States
Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri, 65804
United States
Oncology Hematology Associates
Springfield, Missouri, 65807
United States
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
United States
OptumCare Cancer Care
Las Vegas, Nevada, 89102
United States
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
United States
New Jersey Cancer Center
Belleville, New Jersey, 07109
United States
New York Oncology Hematology
Albany, New York, 12206
United States
Hematology Oncology Associates of Central New York
East Syracuse, New York, 13057
United States
Cayuga Medical Center
Ithaca, New York, 14850
United States
UNC
Chapel Hill, North Carolina, 27599
United States
Duke University
Durham, North Carolina, 27710
United States
Southeastern Medical Oncology Center (SMOC)
Goldsboro, North Carolina, 27534
United States
Aultman Hospital
Canton, Ohio, 44710
United States
TriHealth Cancer Institute
Cincinnati, Ohio, 45220
United States
Ohio State University
Columbus, Ohio, 43210
United States
OhioHealth Reseach Institute
Columbus, Ohio, 43214
United States
Taylor Cancer Research Center
Maumee, Ohio, 43537
United States
Hightower Clinical
Oklahoma City, Oklahoma, 73102
United States
Mercy Clinic Oncology and Hematology - Coletta
Oklahoma City, Oklahoma, 73120
United States
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, 74146
United States
Oregon Oncology Specialists
Salem, Oregon, 97301
United States
Cancer Care Associates of York
York, Pennsylvania, 17403
United States
The Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Baptist Cancer Center
Memphis, Tennessee, 38120
United States
PeaceHealth St. Joseph Medical Center-Bellingham
Bellingham, Washington, 98225
United States
ThedaCare Regional Cancer Center
Appleton, Wisconsin, 54911
United States
Gundersen Health System
La Crosse, Wisconsin, 54601
United States

Collaborators and Investigators

Sponsor: Tempus AI

  • Virginia Rhodes, MD, PRINCIPAL_INVESTIGATOR, Tempus AI, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-22
Study Completion Date2029-06

Study Record Updates

Study Start Date2022-06-22
Study Completion Date2029-06

Terms related to this study

Keywords Provided by Researchers

  • Cancer
  • Oncology
  • Observational
  • Genomic Profiling
  • Precision medicine
  • Non-Small Cell Lung Cancer
  • NSCLC
  • NGS
  • Biomarkers

Additional Relevant MeSH Terms

  • Non-Small Cell Lung Cancer